Terms: = Ovarian cancer AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1 AND Treatment
5 results:
1. Two-phase dual-signal-readout immunosensing platform based on multifunctional carbon nano-onions for ovarian cancer biomarker detection.
Huang Y; Zhang S; Chen Y; Gao L; Dai H; Lin Y
J Mater Chem B; 2023 Aug; 11(30):7209-7216. PubMed ID: 37427755
[TBL] [Abstract] [Full Text] [Related]
2. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract] [Full Text] [Related]
3. [scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma].
Eisenbeilss C; Weizel J; Wolff H
J Dtsch Dermatol Ges; 2003 Jun; 1(6):468-70. PubMed ID: 16295141
[TBL] [Abstract] [Full Text] [Related]
4. Serum copper levels in carcinoma of ovary and cervix.
Saxena P; Yadav S; Salhan S; Bhowmick KT
Indian J Physiol Pharmacol; 2002 Apr; 46(2):159-66. PubMed ID: 12500490
[TBL] [Abstract] [Full Text] [Related]
5. Serum copper level in ovarian carcinoma.
Margalioth EJ; Udassin R; Maor J; Schenker JG
Cancer; 1985 Aug; 56(4):856-9. PubMed ID: 2990656
[TBL] [Abstract] [Full Text] [Related]
